ALISO VIEJO, Calif. and
TORONTO, Aug. 11 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals International (NYSE: VRX) and Biovail Corporation
(NYSE/TSX: BVF) today announced that both companies will hold their
respective special meetings of shareholders on September 27, 2010 for the purpose of considering
and voting upon proposals relating to the companies' previously
announced merger.
Valeant stockholders of record as of the close of business on
August 18, 2010 will be entitled to
notice of, and to attend and vote at, the Valeant special meeting
to be held at 10:00 a.m. local time,
at Valeant's offices located at 14 Main Street, Suite 140, in
Madison, New Jersey 07940.
Registered holders of Biovail common shares as of the close
of business on August 18, 2010 will
be entitled to notice of, and to attend and vote at, the Biovail
special meeting to be held at 10:00
a.m. local time, at Canadian Broadcasting Centre, Glenn
Gould Studio, 250 Front Street West, Toronto, Ontario.
About Valeant
Valeant Pharmaceuticals International (NYSE: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of neurology and dermatology. More
information about Valeant can be found at www.valeant.com.
About Biovail
Biovail Corporation (NYSE: BVF) is a specialty pharmaceutical
company engaged in the formulation, clinical testing, registration,
manufacture, and commercialization of pharmaceutical products.
The Company is focused on the development and
commercialization of medicines that address unmet medical needs in
niche specialty central nervous system (CNS) markets. For
more information about Biovail, visit the Company's Web site at
www.biovail.com.
Additional Information
In connection with the proposed merger, Biovail has filed with
the Securities and Exchange Commission (the "SEC") a Registration
Statement on Form S-4 that includes a preliminary joint proxy
statement of Valeant and Biovail that also constitutes a prospectus
of Biovail. Valeant and Biovail will mail the definitive
joint proxy statement/prospectus to their respective shareholders.
INVESTORS ARE URGED TO READ THE PRELIMINARY JOINT PROXY
STATEMENT/PROSPECTUS AND THE DEFINITIVE VERSION THEREOF WHEN IT
BECOMES AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE PROPOSED TRANSACTION. Investors may obtain the
preliminary joint proxy statement/prospectus and the definitive
version thereof when it becomes available, as well as other filings
containing information about Valeant and Biovail, free of charge,
at the website maintained by the SEC at www.sec.gov and, in
Biovail's case, on SEDAR at www.sedar.com. Investors may also
obtain these documents, free of charge, from Valeant's website
(www.valeant.com) under the tab "Investor Relations" and then under
the heading "SEC Filings," or by directing a request to Valeant,
One Enterprise, Aliso Viejo,
California, 92656, Attention: Corporate Secretary.
Investors may also obtain these documents, free of charge,
from Biovail's website (www.biovail.com) under the tab "Investor
Relations" and then under the heading "Regulatory Filings" and then
under the item "Current SEC Filings," or by directing a request to
Biovail, 7150 Mississauga Road, Mississauga, Ontario, Canada, L5N 8M5,
Attention: Corporate Secretary.
The respective directors and executive officers of Valeant and
Biovail and other persons may be deemed to be participants in the
solicitation of proxies in respect of the proposed transaction.
Information regarding Valeant's directors and executive
officers is available in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2009,
which was filed with the SEC on February 24,
2010, and in its definitive proxy statement filed with the
SEC by Valeant on March 25, 2010.
Information regarding Biovail's directors and executive
officers is available in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2009,
which was filed with the SEC on February 26,
2010, and in its definitive proxy statement filed with the
SEC and the Canadian Securities Administrators (the "CSA") by
Biovail on April 21, 2010.
Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect
interests, by security holdings or otherwise, is contained in the
preliminary joint proxy statement/prospectus filed with the SEC.
These documents can be obtained free of charge from the
sources indicated above. Other information regarding the
interests of the participants in the proxy solicitation will be
included in the joint proxy statement/prospectus and other relevant
materials to be filed with the SEC and the CSA when they become
available. This communication shall not constitute an offer
to sell or the solicitation of an offer to sell or the solicitation
of an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act of 1933, as
amended.
(Logo:
http://photos.prnewswire.com/prnh/20081125/VALEANTLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
Contact
Information:
|
|
|
|
|
|
Contact for
Valeant
|
Contact for
Biovail
|
|
Laurie W. Little
|
Nelson F. Isabel
|
|
949-461-6002
|
905-286-3000
|
|
laurie.little@valeant.com
|
ir@biovail.com
|
|
|
|
SOURCE Valeant Pharmaceuticals International
Copyright . 11 PR Newswire